CUSIP: 03237H101
Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
109,540,561
-
Total 13F shares
-
81,690,006
-
Share change
-
+7,785,015
-
Total reported value
-
$523,632,250
-
Put/Call ratio
-
7.2%
-
Price per share
-
$6.41
-
Number of holders
-
131
-
Value change
-
+$57,316,535
-
Number of buys
-
67
-
Number of sells
-
74
Quarterly Holders Quick Answers
What is CUSIP 03237H101?
CUSIP 03237H101 identifies AMLX - Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2025
-
Previous quarter:
Q1 2025
Recent filing periods for CUSIP 03237H101:
Institutional Holders of Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) as of Q2 2025
As of 30 Jun 2025,
Amylyx Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (AMLX) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
81,690,006 shares.
The largest 10 holders included
ADAGE CAPITAL PARTNERS GP, L.L.C., PERCEPTIVE ADVISORS LLC, TCG Crossover Management, LLC, BlackRock, Inc., Point72 Asset Management, L.P., VANGUARD GROUP INC, Saturn V Capital Management LP, FMR LLC, Nantahala Capital Management, LLC, and 683 Capital Management, LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.